Growth funding CRO Analytics has secured multiple funding milestones including Series A investments from Ben Franklin Technology Partners and related funds, signaling investor confidence and potential for scaled go-to-market initiatives or expanded data capabilities.

Industry niche Operates in pharmaceutical manufacturing focused on outsourced clinical research performance data, presenting a specialized value proposition for CROs, biotech sponsors, and clinical trial sites seeking quality indicators and benchmark analytics.

Executive leadership Led by veteran biopharma expert Peter Malamis and marketing professor Dr. Michael Howley, the company combines deep domain knowledge with strategic market insights, which can be leveraged in high-level partnerships and enterprise sales conversations.

Platform traction Launched Performer, a cloud-based Clinical Trial Quality System, and secured industry recognition and partnerships, indicating a mature product with potential for upsell opportunities to current users and referrals from industry bodies.

Growth potential customers Active collaboration with industry groups such as ACRP and recognition as a Company to Watch suggests ready channels for expanding customer acquisition, including pilot programs, site assessments, and validation projects with CROs and research organizations.